Disease · EFO_1001923
varicose ulcer
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. varicose ulcer. Diseases, record EFO_1001923. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001923
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- varicose ulcer
- Open Targets ID
- EFO_1001923
- Other names
- Stasis Ulcer, Venous Hypertension Ulcers, Venous Stasis Ulcers, Venous Ulcer
- Highest stage of its drugs
- Approval, for 2 of its 18 drugs, from DailyMed
Source Open Targets
Drugs18
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GLYCERIN | CHEMBL692 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ZINC OXIDE | CHEMBL3988900 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CALCIUM DOBESILATE | CHEMBL2106191 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN GLARGINE | CHEMBL1201497 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SULODEXIDE | CHEMBL2108086 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| THROMBIN | CHEMBL2108110 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| STEM BROMELAIN | CHEMBL4298054 | Enzyme | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| NITRIC OXIDE | CHEMBL1200689 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REGRAMOSTIM | CHEMBL2107881 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 18
See all 18 drugsTargets26
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SCN4A | Sodium channel alpha subunit | 2 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Unknown | https://conductscience.org/library/genes/6329 | Drugs and targets |
| ADRA1A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/152 | Drugs and targets |
| ADRB1 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor | 1 | Adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/155 | Drugs and targets |
1 to 10 of 26
See all 26 targetsTrials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02158806 | Low Dose Aspirin for Venous Leg Ulcers | Phase 3 | 251 | 2019-01-04 | Venous Leg Ulcer | ASPIRIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00832091 | Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers | Phase 2 | 72 | 2010-03-24 | Venous Stasis Ulcers | THYMOSIN | Its record names the disease | ClinicalTrials.gov |
| NCT03363633 | Perforator Vein Injection for Symptomatic Venous Disease | Not applicable | 12 | 2018-02-23 | Venous Disease | SODIUM TETRADECYL SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT05707169 | Comparison of Zero- and Two-centimeter Distance From Sapheno-femoral Junction in Laser Ablation of Varicose Vein | Not applicable | 800 | Varicose Veins, Venous Reflux, Venous Insufficiency, Venous Leg Ulcer | EPINEPHRINE, LEVOBUPIVACAINE, LIDOCAINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05005052 | Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities | Phase 3 | 290 | Chronic Venous Disease, Chronic Insufficiency Venous | SULODEXIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00979836 | Calcium Dobesilate for Chronic Venous Wounds | Phase 3 | 230 | Ulcer | CALCIUM DOBESILATE | Its record names the disease | ClinicalTrials.gov | |
| NCT03588130 | A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers | Phase 2 | 120 | Venous Leg Ulcer | STEM BROMELAIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02333123 | Aspirin for Venous Ulcers: Randomised Trial (AVURT) | Phase 2 | 26 | Venous Leg Ulcer | ASPIRIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02802995 | Safety And Efficacy Of Topical Platelet Rich Plasma And Thrombin Coagulum | Phase 3 | 15 | Stasis Ulcer | THROMBIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04310280 | Effects of Local Insulin on Varicose Ulcers for Wound Healing | Phase 3 | 13 | Chronic Venous Disease, Varicose Ulcer, Wound Healing, Insulin, Angiogenesis | INSULIN GLARGINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Aspirin vs Placebo: Number of Participants With Adherence to Treatment | 92 of 125 | 92 of 126 | 251 | NCT02158806 | Trial comparisons |
| Aspirin vs Placebo: deaths from any cause | 2 of 125 | 0 of 126 | 251 | NCT02158806 | Trial comparisons |
| Aspirin vs Placebo: Number of Participants With Healed Venous Leg Ulcers | 88 of 125 | 101 of 126 | 251 | NCT02158806 | Trial comparisons |
| Aspirin vs Placebo: serious adverse events | 11 of 125 | 10 of 126 | 251 | NCT02158806 | Trial comparisons |
| Thymosin Beta 4 (Tβ4) at 3 Doses vs Placebo: Wound Healing (Wound Closure Without Drainage) by Applying Tβ4 Gel Once Daily for up to 84 Days to Patients With Venous Stasis (VS) Ulcers | 12 of 55 | 4 of 17 | 72 | NCT00832091 | Trial comparisons |
| Thymosin Beta 4 (Tβ4) at 3 Doses vs Placebo: serious adverse events | 3 of 55 | 1 of 17 | 72 | NCT00832091 | Trial comparisons |
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001923
GET https://conductscience.org/api/diseases/v1/EFO_1001923/targets?page=2